Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer
Abequolixron in combination with docetaxel in heavily-pretreated NSCLC and SCLC is well tolerated and demonstrates encouraging preliminary clinical activity January 05, 2023 08:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics,
Inspirna to Present at the Evercore ISI Annual HealthCONx Conference
November 17, 2022 08:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced today that Chief Executive Officer Masoud Tavazoie, M.D., Ph.D., and Chief Operating Officer David Darst, MBA, will participate
Inspirna Raises $50 Million in Series D Financing
Funding to further support company in advancing its clinical stage oncology programs NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced that it has raised $50 million in a Series D financing round, co-led by
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer
Favorable efficacy and safety support further development of RGX-202-01 in advanced or metastatic second-line colorectal cancer NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today data from the ongoing Phase 1b clinical trial
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ORR of 50% and median PFS of 11.8 months in patients with KRAS mutant advanced colorectal cancer (CRC) treated in the second-line Favorable safety profile with a majority of TEAEs Grade 2 or lower, and no DLTs observed Overall efficacy and safety
Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that it will present a poster at the 2022 American Society of Clinical Oncology
Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference
New York, NY – April 7, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 21st Annual Needham Virtual Healthcare Conference